Pregabalin Capsule
Product Images NDC 80425-0026

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0026). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1

A line graph depicting percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg, 100 mg, 25 mg taken three times a day, and placebo. The graph shows decreasing patient improvement percentages as pain improvement increases, with Pregabalin 200 mg line generally above others, indicating higher patient improvement rates relative to lower doses and placebo.*

FDA Label Image

Fig 10

A Kaplan-Meier survival curve graph comparing Pregabalin and placebo over 180 days. The vertical axis shows the estimated percentage of subjects without LTR, while the horizontal axis represents time in days. Two lines, solid for Pregabalin and dashed for placebo, depict the rate of subjects remaining event-free over time.*

FDA Label Image

Fig 11

A line chart comparing the percent of subjects improved over a range of percent improvement from baseline to week 12 BOCF. The graph includes two lines representing Pregabalin and Placebo, illustrating subject improvement percentages across different improvement thresholds.*

FDA Label Image

Fig 12

A line graph depicting the percent improved from baseline to Week 16 BOCF on the x-axis against the percent of subjects improved on the y-axis. Two lines compare Pregabalin and Placebo, showing higher improvement percentages for Pregabalin across the range.*

FDA Label Image

Fig 2

A line chart showing percent of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. Two lines compare Pregabalin 100 mg three times a day and placebo effects over the range of pain improvement percentages.*

FDA Label Image

Fig 3

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day, compared to a placebo. The x-axis represents percent improvement in pain, while the y-axis shows the percent of patients improved, illustrating dose-dependent patient improvement trends.*

FDA Label Image

Fig 4

A line graph comparing the percent of patients improved versus the percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows descending lines for each group indicating patient response distribution over the range of pain improvement percentages.*

FDA Label Image

Fig 5

A line graph depicting percent improvement in pain from baseline versus percent of patients improved, comparing Pregabalin 50 mg and 100 mg taken three times a day against placebo. The graph shows trends in pain relief over a range of improvement percentages.*

FDA Label Image

Fig 6

A bar chart depicting responder rates (%) from two studies, E1 and E3, comparing placebo and different pregabalin dosages. The x-axis shows treatment groups with placebo and varying doses (50 mg/day to 600 mg/day) given BID or TID, and the y-axis shows responder rate percentages from 0% to 60%. Bars indicate increased responder rates with higher pregabalin doses compared to placebo, with statistical significance noted for several groups.*

FDA Label Image

Fig 7

A line graph showing seizure reduction (median % change from baseline) versus dose (mg/day) across four studies: Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID. The graph plots dose groups from 0 (placebo) to 600 mg/day, with all shown p-values indicating statistically significant seizure reduction compared to placebo.*

FDA Label Image

Fig 9

A line graph showing percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares three daily doses of Pregabalin (600 mg, 450 mg, 300 mg) and a placebo, illustrating patient improvement trends across increasing pain improvement percentages.*

FDA Label Image

Pregabalin 50mg Cap Qty 60 Ndc 80425 0026

Packaging label for Pregabalin 50 mg capsules, package of 60, labeled by Advanced Rx of Tennessee, LLC, Nashville, TN. The label compares this product to Lyrica and includes NDC 80425-0026-01, lot number 50PRG623, and storage instructions between 20°C and 25°C (68°F - 77°F).*

FDA Label Image

Pregabalin 50mg Cap Qty 90 Ndc 80425 0026

Label for Pregabalin 50 mg capsules by Advanced Rx of Tennessee, LLC. The label states prescription drug status, provides an NDC number (80425-0026-03), and includes storage instructions (store at room temperature 20°-25°C). It also includes packaging information, cautionary federal transfer prohibition, and a lot/expiration date.*

FDA Label Image

Structure

Chemical structure of Pregabalin, showing the molecular arrangement including an isobutyl group, amino group, ketone, and carboxyl group, consistent with the active ingredient Pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.